

In the Claims

1. (Currently Amended) A method for treatment ~~or prevention of snoring, sleep apnea or sudden infant death syndrome~~ and for improvement of nasal breathing in mammals, ~~said method~~ comprising a step of administering to an individual subject in need thereof nasally, ~~[[or]] pharyngeally, or nasally and pharyngeally,~~ a liquid or a solid composition consisting of from about ~~0.01~~ 2 mg to about 200 mg per ml of ~~[[%-an]]~~ alkylaryl polyether alcohol polymer alone or in admixture with a pharmaceutically acceptable excipient, diluent or both, administered to the individual in need thereof daily before going to bed in an aerosol, powder or spray having a particle sizes larger then 5 to about 100 microns.

2. (Currently Amended) The method of claim 1, wherein the treatment is repeated during the night, wherein a maximum dose of alkylaryl polyether alcohol polymer administered per day is 3000 mg and wherein said composition is applied from antegrade or from retrograde.

3. (Original) The method of claim 1, wherein the alkylaryl polyether alcohol polymer is tyloxapol.

4. (Currently Amended) The method of claim 3 wherein the composition is formulated as a nasal or pharyngeal ~~spray, as a nasal solution, as a dry powder, as a lozenge or as a nasal aerosol~~ having a particle size about 10 microns.

5. (Currently Amended) The method of claim 4 ~~useful for treatment and prevention of snoring in humans~~ comprising administration of from about ~~0.2~~ 10 to about 200 mg per ml ~~[[%]]~~

~~of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.~~

6. (Currently Amended) The method of claim 5 comprising administration of ~~from about 1 to~~ the aerosol comprising about 10 mg [[%]] of tyloxapol alone or in admixture with about 50 mg of glycerol and 20 mg of sodium bicarbonate or sodium hydrogen per one ml of an aqueous solution or a normal or diluted saline ~~a pharmaceutically acceptable excipient, diluent or both.~~

7. (Currently Amended) The method of claim 3 [[6]] wherein the composition is formulated as the nasal or pharyngeal spray or solution.

8. (Currently Amended) The method of claim 7 comprising administration of about 10 mg of tyloxapol in admixture with about 50 mg of glycerol and 20 mg of sodium bicarbonate or sodium hydrogen per ml of a diluent administered as a squirt into each nostril, pharynx or to each nostril and pharynx.

9. (Currently Amended) ~~The~~ A method of ~~claim 4~~ useful for treatment ~~and prevention~~ of sleep apnea in humans comprising administration of a liquid or solid composition consisting of from about 5 mg 0.5 to about 200 mg per ml [[%]] of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both, administered to the individual in need thereof daily before going to bed in an aerosol, powder or spray having a particle sizes larger then 5 to about 100 microns.

10. (Currently Amended) The method of claim 9 wherein the composition is formulated as a nasal or pharyngeal spray,

comprising ~~administration of~~ from about 5 mg to about 150 mg [[%]] of tyloxapol ~~alone or~~ in admixture with about 20 mg of sodium bicarbonate or sodium hydrogen and 50 mg of glycerol per ml of a diluent administered as two or three squirts into each nostril, pharyngeally, or both before bed time ~~a pharmaceutically acceptable excipient, diluent or both.~~

11. (Currently Amended) The method of claim ~~10~~ wherein the composition is formulated as ~~the nasal or pharyngeal spray~~ an aerosol having particle sizes of about 10 microns.

12. (Currently Amended) The method of claim 11 comprising administration of about 15 mg per ml [[%]] of tyloxapol ~~alone or~~ in admixture with about 20 mg of sodium bicarbonate and 50 mg of glycerol per ml of a diluent administered as the aerosol pharyngeally before bed time ~~a pharmaceutically acceptable excipient, diluent or both.~~

13. (Currently Amended) ~~The A~~ method ~~of claim 4~~ useful for treatment ~~and prevention~~ of sudden infant death syndrome in infants comprising a nasal or pharyngeal administration to an infant of a liquid or solid composition consisting of from about 0.01 0.1 to about 50 mg per ml [[%]] of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both, as a nasal or pharyngeal spray, solution or aerosol having a particle sizes from about 5 to about 100 microns.

14. (Currently Amended) The method of claim 13 comprising administration of from about ~~0.1~~ 1 to about 20 mg per ml [[%]] of tyloxapol as a nasal or pharyngeal spray or liquid aerosol ~~alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.~~

15. (Currently Amended) The method of claim 14 wherein the composition is formulated as the nasal or pharyngeal spray or ~~nasal~~ solution.

16. (Currently Amended) The method of claim 15 comprising administration of about ~~[[0.1%]]~~ 1 mg of tyloxapol ~~alone or in admixture with a pharmaceutically acceptable excipient, diluent or both~~ in 1-3 drops of a solution to ~~[[an]]~~ the infant before sleep.

17. (Currently Amended) ~~[[The]]~~ A method ~~of claim 4 useful~~ for improvement of nasal breathing in humans comprising administration of from about ~~[[0.2]]~~ 2 mg to about ~~[[20%]]~~ 200 mg of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

18. (Currently Amended) The method of claim 17 useful for improvement of nasal breathing during physical activity or for improvement of nasal breathing impaired due to a disease, infection or surgery by administering to a subject in need of such treatment the composition consisting of from about ~~[[0.5]]~~ 5 mg to about ~~[[10%]]~~ 100 mg of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

19. (Currently Amended) The method of claim 18 wherein the physical activity is diving, mountain hiking, high altitude mountain climbing or flying and wherein the composition is formulated as the nasal or pharyngeal spray, solution or drops ~~or lozenge~~.

20. (Currently Amended) The method of claim 19 wherein the nasal drops, solution or spray ~~or lozenge~~ contain about

[[1%]] 10 mg of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

21. (Currently Amended) The method of claim [[4]] useful for improvement of nasal breathing in animals.

22. (Currently Amended) The method of claim 21 wherein the treatment for improvement of nasal breathing in animals comprises administration of the nasal spray consisting of from about [[0.2]] 2 mg to about [[20%]] 200 mg of tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.

23. (Currently Amended) The method of claim 22 comprising administration of from about 50 mg to about 150 mg [[%]] of ~~tyloxapol alone or in admixture with a pharmaceutically acceptable excipient, diluent or both.~~

24. (Canceled).

25. (Currently Amended) A device for administration of a nasal or pharyngeal composition consisting of from about [[0.01]] 2 mg to [[20%]] 200 mg of alkylaryl polyether alcohol polymer alone or in admixture with a pharmaceutically acceptable excipient, diluent or both, said device suitable for administration of said composition for treatment and prevention of snoring, sleep apnea, sudden infant death syndrome or for improvement of nasal breathing.

26. (Currently Amended) The device of claim 25 wherein said device is a spray container, spray vial, spray pump, atomizer, nebulizer, aerosolizer or dry powder inhaler,

~~humidifier or a mask.~~

27. (Withdrawn).

28. (Currently Amended) The device of claim 26, wherein the device is ~~[[a]]~~ the spray container, said container suitable for administration of ~~[[the]]~~ said composition to a nasal or upper pharyngeal mucosa using an extension nozzle.

29. (Currently Amended) The device of claim ~~[[28]]~~ 26 wherein ~~[[the]]~~ said composition is formulated as a dry powder and the device is the dry powder inhaler.

Claims 30 -37 (Canceled)